Market Access
Solution Spotlight: Acumetis Model Builder
Sponsored

Solution Spotlight: Acumetis Model Builder

Acumetis Model Builder is a web-based platform that generates complete, formula-linked Excel cost-effectiveness and budget impact models in minutes.

Articles
Market access in early stage development: essential to the licensing process?

Market access in early stage development: essential to the l...

In our partnerships & licensing month, Samantha Morrison questions whether market access in early stage development is essential to the licensing process. In the 1990s, pharmaceutical companies could bank on a successful drug launch if they could prove that their drug was...

Articles
Market access in oncology

Market access in oncology

Dr Usman Iqbal, an expert in relative medical value development and evidence generation in oncology, speaks with pharmaphorum around challenges within that space. Dr Usman Iqbal is responsible for developing product value for Sanofi’s oncology...

Articles
Tunnah’s musings: sharing lessons in pharma social media

Tunnah’s musings: sharing lessons in pharma social media

In his last musings of 2012, Paul Tunnah looks back on two social media workshops and the most common questions arising around this digital engagement in the pharma space. I never set out to teach people about social media and certainly don’t consider myself to be an expert. But the facts are that social media has become …

Sales & Marketing

Sales & Marketing
Solution Spotlight: BrandPRO Biopharma
Sponsored

Solution Spotlight: BrandPRO Biopharma

Strong strategy on paper can unravel when priorities collide. BrandPRO Biopharma gives pharmaceutical teams a place to put their decisions to the test

Digital

Market Access

Market Access
Solution Spotlight: Acumetis Model Builder
Sponsored

Solution Spotlight: Acumetis Model Builder

Acumetis Model Builder is a web-based platform that generates complete, formula-linked Excel cost-effectiveness and budget impact models in minutes.

Editor's Picks

  1. Boehringer forges $7bn alliance with China's SBP Group News
  2. Lilly partners with Hims & Hers on obesity drug sales
  3. UK women's health firm Theramex sold for around £2.2bn
  4. What do midterms mean for Trump's pharma and health agenda?
  5. NICE backs Keytruda/Padcev combo for bladder cancer

Newsletters and Deep Dive
digital magazine

Oncology

more

Patients

more

R&D

more